Muhammad Akhlaq

Dr. Muhammad Akhlaq

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2024 in Journal of Health and Rehabilitation Research
Verified
Journal Article
Open access
PDF file
HAHafiz Muhammad Usman Abid
Hafiz Muhammad Usman Abid
MSMuhammad Sajid
Muhammad Sajid
IHInaam Ul Haq
Inaam Ul Haq
MAMuhammad Akhlaq
Muhammad Akhlaq
GZGohar Zubair
Gohar Zubair
MKMuhammad Shahzad Khan
Muhammad Shahzad Khan
Background: Reactive oxygen species (ROS) have been implicated in the pathogenesis of various diseases, emphasizing the importance of antioxidants in maintaining cellular homeostasis. Raphanus raphanistrum, commonly known as wild radish, has been traditionally used for its medicinal properties, including antioxidant, immunomodulatory, and antifungal effects. The plant is rich in bioactive compounds such as flavonoids, isothiocyanates, and vitamins, which contribute to its therapeutic potential. Objective: This study aimed to evaluate the antioxidant, immunomodulatory, and antifungal activities of Raphanus raphanistrum extracts and to compare these activities with standard controls. Methods: Fresh Raphanus raphanistrum plants were collected, and extracts were prepared using methanol, chloroform, and water. The antioxidant activity was assessed using the DPPH radical scavenging assay. Immunomodulatory activity was evaluated through the luminol-enhanced chemiluminescence assay in whole blood and polymorphonuclear leukocytes (PMNS), measuring the oxidative burst. The antifungal activity was determined using the agar disk diffusion method against six pathogenic fungi. The statistical analysis was performed using SPSS version 25, with results presented as mean ± standard deviation for antioxidant and antifungal assays, and mean ± standard error for immunomodulatory activity. Results: The methanol extract exhibited significant antioxidant activity with DPPH scavenging percentages ranging from 56.55% at 150 µg/ml to 87.08% at 850 µg/ml. Immunomodulatory activity showed IC50 values of 37.8 µg/ml in whole blood and 18.9 µg/ml in PMNS for the methanol extract. The antifungal activity against Candida albicans showed zones of inhibition increasing from 15 mm at 150 µg/ml to 22 mm at 850 µg/ml. These activities were compared to standard controls, including ascorbic acid for antioxidant, ibuprofen for immunomodulatory, and miconazole for antifungal assays, demonstrating the extracts' competitive potential. Conclusion: Raphanus raphanistrum extracts showed promising antioxidant, immunomodulatory, and antifungal activities, indicating their potential as natural alternatives for the prevention and treatment of related diseases. Further in vivo studies and isolation of active compounds are recommended to fully understand the mechanisms and therapeutic applications.

25 July 2025 in Journal of Agriculture and Biology
Verified
Journal Article
Open access
PDF file
SNShabnam Niaz
Shabnam Niaz
NANisar Ahmed
Nisar Ahmed
MAMuhammad Akhlaq
Muhammad Akhlaq
MWMuhammad Waleed
Muhammad Waleed
Durum wheat (Triticum durum L.) is an allotetraploid crop species with relatively low gluten content, commonly used in the preparation of pasta, couscous, noodles, macaroni, and flatbreads. The present study was designed to assess the extent of genetic diversity in a global collection of durum wheat accessions grown under the climatic conditions of Pakistan, using morphological traits, protein profiles, and DNA-based markers. A total of 175 accessions were cultivated for two successive years in separate fields of the Azad Kashmir region. Although molecular analysis was conducted only on a representative subset of 30 accessions, it provided useful but preliminary insights into genetic diversity. Future studies with larger datasets are needed to strengthen these results. Analysis of variance revealed highly significant F-values for both genotypes and genotype × year interactions across 18 morphological traits. Seed storage proteins of the genotypes were profiled through SDS-PAGE, which yielded 719 scorable bands from 161 accessions, average of 4.5 distinct protein bands per genotype, each considered as an allelic variant. Considerable variation in genetic distance (GD = 0–100%) was observed; 27 comparisons showed complete homozygosity (GD = 0%), while 252 comparisons exhibited full dissimilarity (GD = 100%) at protein loci. For molecular analysis, 30 randomly selected genotypes were evaluated with 40 RAPD and 50 SSR primer sets. RAPD markers produced 92.05% polymorphism, with genetic distances ranging from 0.00 to 32%. Cluster analysis grouped the 30 genotypes into two main clusters. Similarly, SSR primers were mostly polymorphic, generating 174 fragments in total, with an average of 3.44 bands per primer and 2–7 bands per locus. Genetic distance based on SSR data ranged between 2% and 38%, and cluster analysis again separated the genotypes into two major groups.

9 January 2025 in Journal of Medical & Health Sciences Review
Verified
Journal Article
Open access
PDF file
MAMuhammad Akhlaq
Muhammad Akhlaq
MSMuhammad Saqlain
Muhammad Saqlain
ZWZunaira Wasif
Zunaira Wasif
AHAbdul Hanan
Abdul Hanan
AIAyesha Iddrise
Ayesha Iddrise
MAMuhammad Khaleeq Alum
Muhammad Khaleeq Alum
Nanotechnology has emerged as a transformative approach in cancer therapy, offering innovative solutions for improving drug delivery, diagnostics, and treatment precision. At the core of this advancement are nanoparticles, engineered to specifically target cancer cells while minimizing damage to healthy tissues. Their unique nanoscale properties allow for enhanced drug stability, selective delivery, and controlled release, overcoming many limitations of conventional therapies such as drug resistance, toxicity, and non-specific targeting. This review explores various types of nanoparticles used in cancer treatment, including metallic nanoparticles (e.g., gold and silver), polymeric nanoparticles (e.g., PLGA), and lipid-based nanoparticles (e.g., liposomes and solid lipid nanoparticles). Metallic nanoparticles provide versatile platforms for drug delivery and photothermal therapy, while polymeric nanoparticles offer sustained drug release and biodegradability. Lipid-based systems, known for their biocompatibility, facilitate targeted drug accumulation in tumors through both passive and active targeting mechanisms. The review also highlights the ability of nanoparticles to respond to stimuli such as pH and temperature changes, enabling site-specific drug release within the tumor microenvironment. Additionally, it discusses challenges related to the safety, scalability, and regulatory approval of nanoparticle-based therapies, which must be addressed for clinical translation. Overall, the integration of nanotechnology in oncology represents a promising frontier for developing next-generation cancer therapies. By enhancing treatment specificity and reducing adverse effects, nanoparticles hold the potential to revolutionize cancer care and significantly improve patient outcomes.

1 January 2025 in Kashf Journal of Multidisciplinary Research
Verified
Journal Article
Open access
PDF file
MAMuhammad Akhlaq
Muhammad Akhlaq
MSMuhammad Shoaib
Muhammad Shoaib
UKUm e Kulsoom
Um e Kulsoom
HKHamda Tanzeem Khan
Hamda Tanzeem Khan
MAMuhammad Khaleeq Alum
Muhammad Khaleeq Alum
Cancer is a leading cause of death worldwide, necessitating the discovery of novel therapeutic agents. Natural products, particularly medicinal plants, are increasingly being explored for their anticancer properties. Oxystelma esculentum, a plant traditionally used in Ayurvedic medicine, is known for its wide range of pharmacological effects. This study investigates the anticancer potential of a hydroalcoholic extract of Oxystelma esculentum against human cancer cell lines. The aerial parts of Oxystelma esculentum were extracted using a 70% ethanol solution, and cytotoxicity was evaluated using MTT and CellTiter-Glo assays. Cancer cells were treated with the extract at concentrations of 100 mg/mL, 250 mg/mL, and 500 mg/mL for 48 hours. The IC50 values were calculated using non-linear regression analysis. The extract demonstrated dose-dependent cytotoxicity in the cancer cell lines, with IC50 values of approximately 230 mg/mL. Cell viability decreased significantly, with a maximum inhibition of 85% at the highest concentration (500 mg/mL). The extract also showed significant ATP depletion in the CellTiter-Glo assay, indicating reduced cellular metabolism. The results suggest that the hydroalcoholic extract of Oxystelma esculentum exhibits potent anticancer activity, likely due to its rich content of bioactive compounds such as flavonoids, saponins, and phenolic acids. These findings indicate that Oxystelma esculentum has the potential to be developed into a plant-based anticancer therapy. Further studies are warranted to elucidate the molecular mechanisms involved and to validate the efficacy of the extract in vivo.

16 November 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
MAMuhammad Akhlaq
Muhammad Akhlaq
Green-synthesised silver/silver chloride (Ag/AgCl) nanoparticles carry a surface layer of the plant constituents that reduce and cap them, and that capping layer is part of what a biological system meets. We profiled the safety-related behaviour of twelve capping phytoconstituents of Oxystelma esculentum Ag/AgCl nanoparticles epicatechin, kaempferol, lupeol, stigmasterol, esculin, chlorogenic acid, gallic acid, 4-hydroxybenzoic acid, caffeic acid, ferulic acid and coumarin, with silybin as a reference standard across five computational work packages: physicochemical and drug-likeness descriptors, structural-alert screening, toxicity prediction with two independent predictors, docking against a cardiac, endocrine and cytochrome P450 panel, and a reasoned safety synthesis. No constituent was predicted hepatotoxic by ProTox 3.0, and none was predicted mutagenic by the same predictor, but the predictors disagreed on mutagenicity for three constituents and on hepatotoxicity for one, and both disagreements are reported rather than resolved by fiat. Three constituents lupeol, stigmasterol and silybin combined the strongest predicted hERG pore-site binding (−9.09, −7.94 and −8.93 kcal/mol) with positive hERG II predictions, a qualitative agreement that marks them for experimental cardiac follow-up. Coumarin carried the strongest acute-toxicity signal (predicted LD50 196 mg/kg, the only GHS Class 3 value). Lupeol was the most selective binder in the panel: the strongest at CYP3A4 (−10.50 kcal/mol) and hERG yet a non-binder at the androgen receptor, CYP2D6 and CYP1A2. Silybin, the strongest oestrogen-receptor-α binder (−9.29 kcal/mol), was a non-binder at the androgen receptor and CYP1A2 and carried the only predicted cardiotoxicity flag. All findings are predictions, not experimental toxicity data. Two 10 ns molecular dynamics runs support the docked endocrine poses: silybin remained bound in oestrogen receptor α (mean 1.70 protein–ligand hydrogen bonds per frame, anchored at Glu353 in 96% of frames) and epicatechin remained bound in the androgen receptor (mean 2.26 hydrogen bonds per frame, anchored at Thr877 in 53% of frames), with ligand root-mean-square deviation of 0.18 and 0.16 nm after protein fitting.

2 July 2025 in Journal of Medical & Health Sciences Review
Verified
Journal Article
Open access
PDF file
MAMuhammad Akhlaq
Muhammad Akhlaq
MAMuhammad Akram
Muhammad Akram
SKSyed Kazim
Syed Kazim
ASAbbas Shah
Abbas Shah
SSSania Saeed
Sania Saeed
SRSaqlain Raza
Saqlain Raza
Background: Cancer remains one of the leading causes of death worldwide, with conventional drug discovery methods proving time-consuming, costly, and often ineffective in tackling the complexity and heterogeneity of malignancies. Objective: This review aims to explore the transformative role of artificial intelligence (AI), particularly machine learning (ML) and deep learning (DL), in accelerating and refining anti-cancer drug discovery. Methods: The article examines how AI is integrated into various stages of the drug development pipeline, including target identification, virtual screening, structure prediction, and clinical trial design. Emphasis is placed on synergizing AI with natural product-based drug discovery and addressing key computational, ethical, and regulatory challenges. Findings: AI has significantly improved the prediction of molecular properties, reduced attrition rates, and enabled the repurposing of existing drugs for new cancer indications. Virtual screening of phytochemicals and AI-aided solubility predictions are streamlining the path from lab to clinic. Attention mechanisms and transformer models are enhancing interpretability, while AI is optimizing clinical trials and enabling personalized medicine approaches. Conclusion: Artificial intelligence is revolutionizing cancer therapeutics by enabling faster, cost-effective, and personalized drug development. However, integration into routine practice requires addressing data quality, model interpretability, and ethical concerns. Continued interdisciplinary collaboration will be vital to fully harness AI's potential in oncology drug discovery.